Dexamethasone enhances CTLA-4 expression during T cell activation - PubMed (original) (raw)
Dexamethasone enhances CTLA-4 expression during T cell activation
M Xia et al. Cell Mol Life Sci. 1999 Sep.
Abstract
T cell activation is enhanced by the costimulatory interaction of B7 on antigen-presenting cells and CD28 on T cells, resulting in long-term T cell proliferation, differentiation and production of large amounts of cytokines, such as interleukin (IL)-2. CTLA-4 is a co-stimulation receptor that shares 31% homology with CD28 and binds B7 family members with higher affinity. CTLA-4 is transiently expressed intracellularly and on the cell surface following activation of T cells. We have studied the kinetics of CTLA-4 expression and the effects of dexamethasone on CTLA-4 expression during T cell activation in cultures of mouse spleen cells stimulated by a mixture of immobilized anti-CD3 and anti-CD28 monoclonal antibodies (anti-CD3/CD28 mAb) or concanavalin A (ConA). CTLA-4 expression peaked on day 2 and returned to background levels after 7 days. Dexamethasone was found to potentiate CTLA-4 expression in a dose-dependent manner with an EC50 effective concentration 50%) of about 10(-8) M. In contrast, other immunosuppressive agents, such as rapamycin or cyclosporin A had no or an inhibitory effect on CTLA-4 expression, respectively. Dexamethasone also stimulated CD28 expression, but inhibited IL-2R expression during anti-CD3/CD28 mAb-induced mouse splenic T cell activation. Western blot analyses of lysates of activated mouse T cells showed that dexamethasone increased CTLA-4 protein levels twofold during anti-CD3/CD28 mAb-induced activation. Dexamethasone also enhanced CTLA-4 messenger RNA twofold as quantified by ribonuclease protection assay. The effects of dexamethasone on CTLA-4 expression were glucocorticoid-specific and completely inhibited by the glucocorticoid receptor antagonist mifepristone (RU486), indicating that the effect of dexamethasone on CTLA-4 expression is mediated through the glucocorticoid receptor. In conclusion, the immunosuppressive agent dexamethasone actually stimulates CTLA-4 expression, which is involved in downregulation of T cell activation.
Similar articles
- Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK. Linsley PS, et al. J Exp Med. 1992 Dec 1;176(6):1595-604. doi: 10.1084/jem.176.6.1595. J Exp Med. 1992. PMID: 1334116 Free PMC article. - Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation.
Dahlén E, Hedlund G, Dawe K. Dahlén E, et al. J Immunol. 2000 Mar 1;164(5):2444-56. doi: 10.4049/jimmunol.164.5.2444. J Immunol. 2000. PMID: 10679081 - Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P. Vandenborre K, et al. Immunology. 1999 Nov;98(3):413-21. doi: 10.1046/j.1365-2567.1999.00888.x. Immunology. 1999. PMID: 10583602 Free PMC article. - The complexity of the B7-CD28/CTLA-4 costimulatory pathway.
Schweitzer AN, Sharpe AH. Schweitzer AN, et al. Agents Actions Suppl. 1998;49:33-43. doi: 10.1007/978-3-0348-8857-8_6. Agents Actions Suppl. 1998. PMID: 9426826 Review. - Costimulatory regulation of T cell function.
Chambers CA, Allison JP. Chambers CA, et al. Curr Opin Cell Biol. 1999 Apr;11(2):203-10. doi: 10.1016/s0955-0674(99)80027-1. Curr Opin Cell Biol. 1999. PMID: 10209159 Review.
Cited by
- Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.
Mishra DK, Popovski D, Morris SM, Bondoc A, Senthil Kumar S, Girard EJ, Rutka J, Fouladi M, Huang A, Olson JM, Drissi R. Mishra DK, et al. Neuro Oncol. 2024 Feb 2;26(2):226-235. doi: 10.1093/neuonc/noad170. Neuro Oncol. 2024. PMID: 37713135 Free PMC article. Review. - Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19.
Chimote AA, Alshwimi AO, Chirra M, Gawali VS, Powers-Fletcher MV, Hudock KM, Conforti L. Chimote AA, et al. Front Immunol. 2023 Mar 24;14:1143350. doi: 10.3389/fimmu.2023.1143350. eCollection 2023. Front Immunol. 2023. PMID: 37033961 Free PMC article. - Stress-induced immunosuppression affecting immune response to Newcastle disease virus vaccine through "miR-155-CTLA-4" pathway in chickens.
Wen J, Wu Y, Han J, Tian Y, Man C. Wen J, et al. PeerJ. 2023 Feb 27;11:e14529. doi: 10.7717/peerj.14529. eCollection 2023. PeerJ. 2023. PMID: 36874964 Free PMC article. - Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells.
Kim EJ, Kim JY, Choi HY, Lee H, Lee J, Kim MS, Kim YS, Huh KH, Kim BS. Kim EJ, et al. Yonsei Med J. 2021 Feb;62(2):137-148. doi: 10.3349/ymj.2021.62.2.137. Yonsei Med J. 2021. PMID: 33527793 Free PMC article. - Glucocorticoids in T cell development, differentiation and function.
Taves MD, Ashwell JD. Taves MD, et al. Nat Rev Immunol. 2021 Apr;21(4):233-243. doi: 10.1038/s41577-020-00464-0. Epub 2020 Nov 4. Nat Rev Immunol. 2021. PMID: 33149283 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources